HOME >> MEDICINE >> NEWS
Targeting cell fusion as possible way to repair organs, deliver cancer vaccines

of cancer -- can be killed. "Our biofusion research brings a new level of control to the system so the right fusion matches are made to serve therapeutic ends," says Dr. Russell. "It offers a biotechnology platform that provides a way to choose and direct the agents of fusion by getting tumor cells to fuse with dendritic cells -- one cell type in the immune system. The result is biofusion that prompts the immune system to attack the tumor.

"This is important because the exploitation of cell fusion, whether for killing cancer cells, repairing damaged tissues or stimulating the immune system, depends on making sure that it is accurately targeted," he says.

Potential Applications

The ability to fuse tumor cells to treat cancers is one application the Mayo Clinic cancer research team envisions for their biofusion platform.

Another possible application involves cancer vaccines that prevent cancer from progressing or developing. Current vaccine approaches involve taking dendritic cells from cancer patients, feeding the dendritic cells tumor antigens, and then reintroducing the dendritic cells into the patient's body and relying on the body's natural process of "instruction" to help the body create cells that attack cancer. In this natural system, dendritic cells present antigens to other immune cells in a way that effectively "teaches" them what they are to attack.

Dr. Russell believes the biofusion technology would be a better way of "feeding" the dendritic cells the information they need to "learn" what they are to attack.

"Biofusion would involve putting genes in the dendritic cells inside the body that will cause them to fuse directly into tumors at multiple sites in the patient," he says. He notes that Mayo Clinic cancer research colleague Richard Vile, Ph.D., last year successfully fused tumor and dendritic cells to create a hybrid of the two -- but it was not targeted. "So this is not blue-sky stuf
'"/>

Contact: Mary Lawson
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
17-Feb-2004


Page: 1 2 3

Related medicine news :

1. Targeting mutant B-Raf protein reduces melanoma development
2. Jefferson and Molecular Targeting Technologies, Inc. scientists create vaccine for wildlife rabies
3. Targeting bone metastasis and hypercalcemia
4. Effective Obesity Treatment Likely To Require Targeting Of Multiple Weight Control Systems
5. Diffusion-weighted MRI can diagnose mad cow-related disease in humans before symptoms show
6. Article highlights confusion about Homeland Security safety symbols
7. Information fusion research simulates disasters to manage emergency response
8. NHLBI stops sickle cell anemia transfusion study
9. Ongoing transfusions needed to avoid strokes in children with sickle cell disease
10. Blood transfusion poses CJD risk
11. Mayo researchers observe genetic fusion of human, animal cells -may help explain origin of AIDS

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/23/2017)... ... ... Mill”: a story of love and redemption, hope and uncertainty as a girl makes ... “The Inn at the Mill” is the creation of published author, Lois Kulp, who was ... in Berks County on Crow Hill. The inn, the mill and "Post Yokel" ...
(Date:1/23/2017)... ... ... “Some Infallible Characteristics of Christ”: a fascinating and entrancing novel exploring the ... of published author, Rev. Dr. Robert W. Thomas, the third of seven siblings. He ... nineteen, a pastor for over fifteen years. He is a graduate of N.C. College ...
(Date:1/22/2017)... ... January 22, 2017 , ... "Photo Cloud allows FCPX users to add ... slideshow with complete ease," said Christina Austin - CEO of Pixel Film Studios. ... FCPX timeline. Presets include scenes with one, three, four or five focus ...
(Date:1/21/2017)... ... ... is the perfect set of tools for video editors that want to create the illusion ... - CEO of Pixel Film Studios. , Video editors using ProDOF can add realistic ... racking focus from one area into the next. ProDOF comes with 0.5 second, 1.0 ...
(Date:1/21/2017)... ... January 21, 2017 , ... Northern California ... has recently joined their multi-specialty medical group. The dermatology practice provides general dermatologic ... “We’re excited to add this excellent dermatology practice to our group’s medical services,” ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... Stock-Callers.com today presents the following Generic ... CPRX ), Sophiris Bio Inc. (NASDAQ: SPHS ), ... Therapeutics Inc. (NASDAQ: AGRX ). These companies are ... late trade on Friday, January 20 th , 2017, with ... of health care companies in the S&P 500 also were ...
(Date:1/23/2017)... -- ResMed (NYSE : RMD), BMC (Pékin, Chine) et 3B Medical ... se sont mis d,accord sur le règlement mondial de ... 3B seront autorisés à vendre leurs produits existants en ... effectuera le paiement de la décision en une seule ... entre les deux parties. Le règlement n,inclut pas l,admission ...
(Date:1/23/2017)... Jan 23, 2017 InDex Pharmaceuticals Holding AB ... the 12th congress of the European Crohn,s and Colitis Organisation (ECCO). ... a specific focus on inflammatory bowel disease (IBD). The congress is ... 2017. ... are pleased to again having been selected to present data at ...
Breaking Medicine Technology:
Cached News: